Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...
Zymeworks Inc.: Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin ...
Clinical Advisor3h
FDA Drug Approval Decisions Expected in April 2025
The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.
Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...
Medscape19h
Using Preprinted Medication Order Forms to Improve the Safety of Investigational Drug Use
Am J Health Syst Pharm. 2006;63(11):1022-1028. Q: How can potential medication errors be minimized when dispensing investigational drugs to better ensure patient safety and improve adherence to ...
Labroots20h
Labroots 2025 Drug Discovery & Development Poster Winner: Dr. Jong-Hyuk Lee
Labroots’ virtual events are designed to spark impactful scientific discussions while connecting with individuals worldwide ...